REGISTER
Dirk Schadendorf on STARBOARD and First-Line Triplet Therapy in Melanoma
At ESMO 2026, Dirk Schadendorf reviews STARBOARD, a phase 3 trial of encorafenib, binimetinib, and pembrolizumab in advanced BRAF V600-mutant melanoma. He discusses tumor response, progression-free survival, the trade-off with higher toxicity, and the need for longer overall survival follow-up.

0
0
Loading